Johnson & Johnson (JNJ)vsLENZ Therapeutics Inc (LENZ)
JNJ
Johnson & Johnson
$267.34
+3.05%
HEALTHCARE · Cap: $613.02B
LENZ
LENZ Therapeutics Inc
$5.90
-2.64%
HEALTHCARE · Cap: $181.54M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 459007% more annual revenue ($96.36B vs $20.99M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
LENZ
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LENZ
The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LENZ
The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LENZ is a value play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.47 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for neurological disorders, with an emphasis on addressing significant unmet needs in the central nervous system (CNS). Leveraging advanced drug formulation and delivery technologies, the company boasts a robust pipeline of proprietary assets designed to improve patient outcomes. With strategic partnerships and a strong commitment to rigorous clinical research, LENZ is well-positioned for substantial growth and aims to establish itself as a key player in the biopharmaceutical sector, capitalizing on emerging opportunities within the evolving healthcare market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?